Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Total Non-current Liabilities
All obligations due after more than one year.
Editas Medicine, Inc.NASDAQ: EDIT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 17.9% from a year ago
Total non-current liabilities stood at $105.15M at the end of Q1 FY2026, down 17.9% from a year earlier and down 6.9% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Total non-current liabilities amounted to 70.4% of total assets at the end of Q1 FY2026, up 21.8 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -17.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 113M USD
- Year-over-year change
- -13.1%
- 4-year CAGR
- +10.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113M | -13.1% |
| FY2024 | 2024-12-31 | 130.09M | +49.8% |
| FY2023 | 2023-12-31 | 86.84M | -7.2% |
| FY2022 | 2022-12-31 | 93.53M | +21.5% |
| FY2021 | 2021-12-31 | 76.96M | — |
Total Non-current Liabilities vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's Mar 2026 total non-current liabilities of $105.15M is the 4th highest of the 9 companies compared; the peer median is $60.72M.
- Its year-over-year change of -17.9% is the 7th highest of 9, against a peer median of -2.9%.
- Total non-current liabilities amounts to 70.4% of total assets for EDIT, versus a peer median of 17.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $767.38M | +264.8% | -7.6% | 30.0% | |
| Jun 2026 | $238.31M | +40.0% | -27.6% | 17.2% | |
| Mar 2026 | $181.74M | -2.8% | +120.0% | 61.7% | |
| Mar 2026 | $105.15M | -17.9% | +6.5% | 70.4% | |
| Mar 2026 | $61.4M | -34.4% | -24.9% | 8.1% | |
| Mar 2026 | $60.04M | -4.2% | -23.3% | 41.7% | |
| Mar 2026 | $27.31M | -2.3% | -14.7% | 18.3% | |
| Mar 2026 | $22.9M | -3.0% | +0.1% | 8.0% | |
| Mar 2026 | $394K | -35.7% | -4.0% | 0.2% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | $60.72M | -2.9% | -11.2% | 17.8% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 203.52M | 141.52M | 123.65M | 131.54M | 146.65M |
| Short-term Investments | 296.33M | 202.75M | 199.46M | 138.37M | 0 |
| Net Receivables | 267K | 5.15M | 10.19M | 16.27M | 15.18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.34M | 7.53M | 3.14M | 2.07M |
| Total Current Assets | 507.31M | 356.75M | 340.83M | 289.32M | 163.9M |
| Property, Plant & Equipment (Net) | 43.29M | 59.22M | 45.71M | 47.05M | 19.66M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 120.07M | 93.1M | 104.02M | 3.88M | 2.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.81M | 5.25M | 8.59M | 1.35M | 276K |
| Total Non-current Assets | 170.17M | 157.57M | 158.32M | 52.27M | 22.64M |
| Total Assets | 677.48M | 514.32M | 499.15M | 341.59M | 186.53M |
| Account Payables | 5.05M | 9.51M | 8.27M | 5.49M | 2.61M |
| Short-term Debt | 0 | 0 | 12M | 0 | 11.03M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.33M | 8.22M | 8.22M | 11.22M | 44.51M |
| Other Current Liabilities | 10.16M | 10.14M | (723K) | 21.99M | (11.9M) |
| Total Current Liabilities | 46.88M | 60.11M | 63.22M | 77.23M | 46.25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 53.61M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 60.89M | 60.67M | 60.67M | 106.64M | 44.51M |
| Other Non-current Liabilities | 0 | 0 | 1.8M | 3.07M | 2.82M |
| Total Non-current Liabilities | 76.96M | 93.53M | 86.84M | 130.09M | 113M |
| Total Liabilities | 123.84M | 153.64M | 150.06M | 207.32M | 159.25M |
| Common Stock | 7K | 7K | 8K | 8K | 10K |
| Retained Earnings | (857.7M) | (1.08B) | (1.23B) | (1.47B) | (1.63B) |
| Accumulated OCI | (493K) | (3.6M) | 198K | 268K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 553.64M | 360.68M | 349.1M | 134.27M | 27.29M |
| Total Debt | 26.38M | 43.95M | 48.54M | 35.03M | 76.71M |
| Net Debt | (177.14M) | (97.58M) | (75.11M) | (96.51M) | (69.94M) |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.